Brief: Herantis Pharma gets orphan designation in USA for CDNF for treatment of ALS

Herantis Pharma Oyj

11/07/2016 07:12

July 11 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :   
    * The United States Food and Drug Administration FDA has granted orphan designation for 
Herantis Pharma Plc's CDNF for treatment of amyotrophic lateral sclerosis (ALS)  
 
Source text: http://bit.ly/29C1RaM 
 
Further company coverage:  HRTIS.HE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))